Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Tilinca, M
At that point, compounds were added at a final concentration of 10 M, diluted in DMEM with 0.5% FBS
The company was founded in 1992, and over time it moved deeper into custom formulation and private label manufacturing
Not for human consumption, medical use, or clinical application
During this time our bodies produce very little glutathione, which is usually enough to destroy the oxidative effects and our antioxidant shield
35 Key Corporate Highlights Advancing Novel Therapies for Diseases with High Unmet Needs Expected Upcoming Milestones Focus on diseases with well-defined mechanistic Phase 3 LUCIDITY topline data Q3 2026 Avexitide PBH Clinical anticipated in Q3 2026 rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data Commercial launch, if approved, 2027 Avexitide PBH Regulatory anticipated in 2027 First-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug AVEXITIDE designations Phase 1 LUMINA trial Cohort 1 (n=12) biomarker data to be presented at a 1H 2026 AMX0114 ALS Clinical Oral, fixed-dose combination of two medical meeting expected in 1H 2026 small molecules, sodium AMX0035 phenylbutyrate and taurursodiol PBH & Rare IND-enabling studies underway with an Antisense oligonucleotide designed to 2027 AMX0318 Preclinical target calpain-2, a protein involved in IND filing targeted for 2027 Diseases AMX0114 axonal degeneration & neurofilament biology with FDA Fast Track Designation Novel, long-acting GLP-1 AMX0318 receptor antagonist ALS=amyotrophic lateral sclerosis
US$ 25.62
US$ 29.41
US$ 22.03
US$ 20.25
US$ 20.75
US$ 23.89
US$ 26.85
US$ 27.07
